Beyond Unfractionated Heparin and Warfarin

This publication has 38 references indexed in Scilit:

• Factor IXa Inhibitors as Novel Anticoagulants
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2007
• Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized Trial
  JAMA, 2006
• Oral Anticoagulants in Development
  Drugs, 2006
• Emerging anticoagulants for the treatment of venous thromboembolism
  Thrombosis and Haemostasis, 2006
• Discovery of the Novel Antithrombotic Agent 5-Chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): An Oral, Direct Factor Xa Inhibitor
  Journal of Medicinal Chemistry, 2005
• New anticoagulants
  Blood, 2005
• A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation
  Journal of Thrombosis and Haemostasis, 2004
• Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial
  The Lancet, 2003
• Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers
  Circulation, 2002
• Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis
  The Lancet, 2000